Logo
x

Search

Subscribe Now

All Posts by Date

Pfizer and Eli Lilly Report Results of Tanezumab in P-III OA study (A4091057) for Moderate-To-Severe Osteoarthritis (OA) Pain

Pfizer and Eli Lilly Report Results of Tanezumab in P-III OA study (A4091057) for Moderate-To-Severe Osteoarthritis (OA) Pain

  • January 30, 2019
Takeda Reports Results of TAK-003 in P-III TIDES (DEN-301) Trial for Dengue

Takeda Reports Results of TAK-003 in P-III TIDES (DEN-301) Trial for Dengue

  • January 30, 2019
Sumitomo Dainippon's Latuda (lurasidone HCl) Receives NMPA's (CFDA) Approval for Schizophrenia

Sumitomo Dainippon's Latuda (lurasidone HCl) Receives NMPA's (CFDA) Approval for Schizophrenia

  • January 30, 2019
EMA Shifts its Headquarters from London to Amsterdam- The Netherlands

EMA Shifts its Headquarters from London to Amsterdam- The Netherlands

  • January 30, 2019
Neurocrine and Voyager Collaborate to Develop and Commercialize VY-AADC & VY-FXN01 for Parkinson's & Friedreich's Ataxia Disease

Neurocrine and Voyager Collaborate to Develop and Commercialize VY-AADC & VY-FXN01 for Parkinson's & Friedreich's Ataxia D...

  • January 30, 2019
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.